Rude Health | finnCap Life Sciences quarterly sector note
Summary from finnCap Life Sciences: The AIM Healthcare index rose by 13% in 2019, marginally outperforming the AIM All Share (+12%). AIM Healthcare was outperformed by the larger cap FT All Share Health and World Health indices (+25% and +17%, respectively), assisted by M&A activity, sustained rate of regulatory approvals and also the defensive nature of the large cap sector, set amidst Brexit uncertainty and earnings downgrades elsewhere in the market. However, there were 17 finnLife 50 stocks that exhibited double-digit percentage increases in the past 12 months, and a further four that exhibited triple-digit percentage increases; namely Silence Therapeutics (+503%), Shield Therapeutics* (+482%), ReNeuron (+184%) and Ergomed (+126%). We remain optimistic for the sector in 2020, given expected inflection points and superior growth.
To find out more about accessing this quarterly sector note in full, please contact firstname.lastname@example.org
finnCap operates an ‘access-for-all’ approach for corporate research, approved by the FCA and paid for by finnCap’s corporate clients. Register for the finnCap Research Portal